associated with a worse prognosis (Mekontso Dessap et al, 2008; Cecchini et al, 2014) . In addition to an imbalance favouring vasoconstriction (related to haemolysis and nitric oxide scavenging), in situ pulmonary artery thrombosis (PAT) is involved in lung vascular dysfunction observed during ACS (Mekontso Dessap et al, 2011) . More than 30 years ago, Walker et al (1979) emphasized the fact that "the diagnosis of pulmonary thromboembolism in patients with sickle cell disease presenting with ACS is a difficult task", especially because the clinical signs of ACS mimic PAT.
Guidelines on ACS management encourage considering PAT when diagnosing ACS and recommend multi-detector computed tomography (MDCT) angiography in the case of high clinical suspicion (Habibi et al, 2015; Howard et al, 2015) . The diagnostic workup of non-SCD patients with suspected pulmonary embolism starts with an assessment of clinical probability using clinical prediction rules (e.g. revised Geneva score) (Le Gal et al, 2006) , with or without D-dimer testing before considering MDCT angiography (Konstantinides et al, 2014) . During ACS, there is no clinical score or biomarker available to select patients eligible for MDCT angiography (Mekontso Dessap et al, 2011) . Ddimer testing is often positive in the setting of ACS (Mekontso Dessap et al, 2008; Cecchini et al, 2016) . The frequent observation of acute cor pulmonale during ACS, even in the absence of PAT (Mekontso Dessap et al, 2008; Cecchini et al, 2016) , makes echography an inaccurate strategy to assess the probability of PAT in SCD patients. Targeting adult SCD patients who will be assessed by MDCT angiography during ACS is of critical importance in order to avoid unnecessary irradiation of these young patients, because ACS is typically a relapsing disease and PAT is found in only a minority of episodes. The aim of the present study was to elaborate a dedicated clinical risk score for PAT during ACS (PAT-ACS risk score).
Patients and methods

Patients
This was a single-centre retrospective observational study of adult patients with SCD admitted for ACS to a French SCD reference centre between 2007 and 2014. The diagnosis of ACS was defined as an acute illness with fever and/or respiratory symptoms, accompanied by a new pulmonary infiltrate on a chest X-ray in a patient with genetically proven SCD (Ballas et al, 2010) . Patients investigated by MDCT angiography during the ACS episode were included. All MDCT examinations were performed using a 64-row MDCT (Lightspeed VCT, GE Healthcare, Wauwatosa, WI, USA) with standard parameters (Mekontso Dessap et al, 2008; Cecchini et al, 2016) . MDCT images were interpreted by hospital radiologists as part of their clinical work. PAT was defined as a MDCT showing a thrombus up to the segmental level or multiple thrombi at the subsegmental level (Mekontso Dessap et al, 2008; Cecchini et al, 2016) . The following data were recorded: baseline characteristics (including type of haemoglobinopathy, steady-state haemoglobin value, history and long-term treatment for SCD), predisposing factors for venous thromboembolism (e.g. pregnancy, post-partum, active cancer), triggering factors of ACS (extrathoracic pain crisis preceding the ACS, surgery in the previous 15 days, documented bacterial or viral infection, and the 6-weeks post-partum period), the revised Geneva score (Le Gal et al, 2006) , treatment and outcome of ACS. Patients received a standardized treatment protocol for ACS, including red blood cell transfusion (Habibi et al, 2015) and low-molecular-weight heparin prophylactic anticoagulant therapy. Patients diagnosed with PAT as defined above were given therapeutic anticoagulation for 3-6 months.
Statistical analysis
The data were analysed using the SPSS Base 19.0 statistical software package (IBM Corp., Armonk, NY) and R 3.1.2 (The R Foundation for Statistical Computing, Vienna, Austria). Continuous data were expressed as median [25th-75th percentiles] and compared using the Mann-Whitney test. Categorical variables, expressed as percentages, were evaluated using the chisquare test or Fisher's exact test. All factors significantly associated with PAT in univariate analysis were included in a logistic regression multivariate analysis to determine independent risks factors for PAT. Continuous data were converted into categorical variables, with the selection of threshold values based on Youden's method (highest sum sensitivity + specificity) and the beta coefficients of independent risks factors for PAT were used to build the PAT-ACS risk score. To determine score weights, the regression coefficients were rounded to the closest integer. Individual scores were computed for the episodes with complete data on all predictor variables included in the PAT-ACS risk score. Calibration of the model and its discrimination were tested with the Hosmer-Lemeshow goodness-of-fit test (Hosmer & Lemeshow, 1989) and receiver operating characteristic (ROC) analysis, (Egan, 1975) respectively. The accuracy of the PAT-ACS risk score was compared with that of the revised Geneva score using the ROC analysis as proposed by DeLong et al (1988) . All tests were two-tailed, and P values of <0Á05 were considered to be statistically significant.
Ethics
The study was approved by our institutional ethics committee (Comit e de Protection des Personnes Ile de France IX) as a component of standard care.
Results
Of the 466 episodes of ACS screened during the study period, 361 (in 257 patients) were tested for PAT by MDCT and included for analysis. Forty-five and 24 patients presented two or more than two episodes of ACS, respectively. The median time elapsed between two episodes was 372 days. The delay between the diagnosis of ACS and MDCT was 1 [0-2] day. Overall, PAT was diagnosed in 43 episodes (11Á9%, 95% CI 9Á0-15Á7%). Among the 318 episodes without PAT, 13 showed a unique thrombus at the sub-segmental level, and 305 revealed no thrombus.
Patients characteristics
Patients with a PAT during at least one episode of ACS (n = 40) were more likely to have a genotype other than SS, a history of red blood cell allo-immunization or delayed haemolytic transfusion reaction, and had higher baseline haemoglobin values, as compared to their counterparts without PAT (Table I ). Patients with PAT had also been more often hospitalized during the 15 days preceding the index ACS episode, but were less likely to have an identified triggering factor for ACS and to present with pulmonary crackles; they also had higher platelet counts and lower values of PaCO 2 and total bilirubin as compared to their counterparts (Table II) . Except for a lower rate of antibiotic use in patients with PAT, the management and outcome of ACS did not differ between groups (Table SI) .
PAT-ACS risk score
The multivariate analysis (Table III) identified four risk factors, which were included in the final model used to derive the PAT-ACS risk score: a baseline haemoglobin >82 g/l, the lack of a triggering factor for ACS, a platelet count >440 9 10 9 /l and a PaCO 2 <38 mmHg at diagnosis of ACS (Tables SII and SIII) . A complete data set on all 4 predictor variables was available for 325 episodes. The area under the ROC curve for the PAT-ACS risk score was 0Á74 (95% confidence interval [CI] 0Á69-0Á79) and differed significantly from that of the revised Geneva score (0Á63 (95% CI 0Á58-0Á69); P = 0Á04) (Fig 1) . The prevalence of PAT for PAT-ACS risk scores of 0, 1, 2, 3 and 4 was 3%, 7%, 17%, 42% and 67%, respectively (Fig 2) . The negative predictive value was 96Á9%, 94Á2%, 90Á8% and 88Á2% for PAT-ACS risk scores equal or higher than 1, 2, 3 and 4, respectively (Table SIV) . The cut-off value corresponding to the maximal Youden's index (J = 0Á39) was a risk score ≥2, associated with a sensitivity, specificity, positive and negative predictive value of 70%, 69%, 24%, and 94%, respectively (Table SIV) . A sensitivity analysis including only the first episode of ACS found an area under the ROC curve of 0Á74 (95% CI 0Á67-0Á79; P < 0Á001) for the PAT-ACS score ( Figure S1 ).
Discussion
In this study, we identified factors associated with the presence of PAT on MDCT during ACS episodes in adult patients with SCD, and developed a simple and readily available clinical risk score to select patients eligible for MDCT angiography. The PAT-ACS risk score had a fair discrimination and was significantly better than the revised Geneva score in predicting PAT during ACS. , bicarbonate ion; LDH, lactate dehydrogenase; PaCO 2 , partial pressure of arterial carbon dioxide; PaO 2 , partial pressure of arterial oxygen; PAT, pulmonary artery thrombosis; SaO 2 , arterial oxygen saturation. *other factors included flu-like syndrome (n = 11), corticosteroid therapy (n = 3), autologous stem cell transplantation (n = 1), delayed haemolytic transfusion reactions (n = 2), excessive physical exercise (n = 3), status epilepticus (n = 1), meteorological reason (n = 3), heart failure (n = 1), foodborne illness (n = 1), trauma (n = 1), high-altitude travel (n = 2) and catheter-related thrombosis (n = 1).
Risk factors for PAT during ACS
The predictors of the PAT-ACS risk score included a baseline haemoglobin value >82 g/l, the absence of an identified triggering factor, a platelet count >440 9 10 9 /l and a PaCO 2 <38 mmHg at the diagnosis of ACS. The association between a high baseline haemoglobin value and PAT in our study may suggest an association with a hyperviscosity phenotype rather than a haemolytic one (Kato et al, 2007) . The lower bilirubin value in the PAT group at admission reinforces this hypothesis. The association between compound heterozygosity -mostly SC genotype -and PAT in univariate analysis is consistent with previous studies reporting more common thromboembolism 9 /l* 1Á002 (1Á001-1Á004), P = 0Á002 1Á003 (1Á001-1Á005), P = 0Á001 PaCO 2 , per mmHg* 0Á93 (0Á89-0Á98), P = 0Á003 0Á92 (0Á87-0Á97), P = 0Á004 Total bilirubin, per lmol/l* 0Á99 (0Á98-0Á998), P = 0Á02 I/NR 95% CI, 95% confidence interval; I/NR, included in the model, but not retained in the final analysis; OR, odds ratio; PaCO2, partial pressure of arterial carbon dioxide; SCD, sickle cell disease; *at diagnosis of acute chest syndrome.
Fig 1.
Receiver operating characteristic (ROC) curves of the pulmonary artery thrombosis risk score during acute chest syndrome (PAT-ACS risk score, continuous line) and of the revised Geneva score (dashed line).
The area under the ROC curve for the PAT-ACS risk score was 0Á74 (95% confidence interval [CI] 0Á69-0Á79) and differed significantly from that of the revised Geneva score (0Á63 (95% CI 0Á58-0Á69), P = 0Á04. (Ballas et al, 1982; Manci et al, 2003; Naik et al, 2013) . However, the relationship between genotype and thrombosis remains controversial (Naik et al, 2013 (Naik et al, , 2014 . Among the many haemostatic alterations leading to a hypercoagulable state in SCD patients, platelet activation is commonly observed during acute vaso-occlusive episodes (Tomer et al, 2001) , and might mediate the genesis of pulmonary platelet thrombi during ACS (Anea et al, 2016) . The higher platelet count found in our study at the diagnosis of ACS with PAT argues for a contributing role of platelets in pulmonary thrombogenesis. Future studies should assess platelet function during ACS with or without PAT. Other cell types (e.g., neutrophils) may also enhance the interaction of platelets with endothelial cells.
A precipitating factor was less frequently identified in patients with PAT during ACS as compared to their counterparts. This finding is consistent with the landmark cohort study on ACS, which presumed that pulmonary infarction might be a specific cause for ACS (Vichinsky et al, 2000) .
The interpretation of lower PaCO 2 values in patients with PAT is not straightforward, but this finding may reflect a hyperventilation state, which is consistent with the common hypocapnia observed during pulmonary embolism in non-SCD patients (Santolicandro et al, 1995) .
Clinical implications of the PAT-ACS score
Although still debated, the therapeutic implications of diagnosing PAT may be of major clinical importance in SCD. There is a need to include the assessment of PAT in the diagnostic workup of ACS (Habibi et al, 2015; Howard et al, 2015) . No current diagnostic strategy for PAT exists for SCD patients and we herein confirmed that the revised Geneva score was of limited interest in this setting (Mekontso Dessap et al, 2008; Cecchini et al, 2014) . MDCT has risks, including exposure to ionizing radiation with attendant long-term cancer risk (Mathews et al, 2013) , and potential adverse reactions from contrast agents (Kobayashi et al, 2013) . The typical recurrence of ACS in young SCD patients argues for strategies aiming at reducing MDCT exposure, such as the implementation of a clinical risk score for PAT. The PAT-ACS risk score should be validated in an independent cohort prior to broad adoption in routine practice. For the first time, our clinical risk score provides guidance to individualize the management of ACS through the proper use of MDCT and appropriate anticoagulation. The low prevalence of PAT among SCD patients with a PAT-ACS risk score <2 (n = 12/209, 5Á7%) is similar to that of pulmonary embolism in low-risk groups of non-SCD patients which were classified through validated prediction rules (Ceriani et al, 2010) .
While traditional risk factors for venous thromboembolism, such as surger, or pregnancy (Konstantinides et al, 2014) , were not associated with PAT and not included in the PAT-ACS risk score, these factors should not be neglected when evaluating the individual risk of PAT during ACS. In fact, recent hospitalizations were more frequent in the PAT group in univariate analysis. Although peri-operative or peri-partum periods accounted for only a few episodes in our study, SCD was previously demonstrated to be associated with an increased risk of pregnancy-associated venous thromboembolism (James et al, 2006) .
Strengths and limitations
The strengths of our study include its large size, and the use of a homogenous MDCT protocol. Our study has several limitations. First, the selection criteria for MDCT were not predefined; the attending physician made the decision, the reasons for which were not recorded. This may have misled our findings on overall prevalence estimate and predictors of PAT during ACS. Our database was clinicianselected and may therefore be intrinsically skewed as we could not compare it to patients who did not undergo CT angiography. The lack of centralized review of MDCTs may also contribute to the lower prevalence estimate (as compared to that of a previous report) (Mekontso Dessap et al, 2008) . Second, patients having a unique thrombus at the sub-segmental level were allocated to the group without PAT. However, the clinical significance of sub-segmental defects on MDCT is controversial in non-SCD patients (Konstantinides et al, 2014) , and withholding anticoagulation therapy in such cases appear to be safe (Stein et al, 2012) . Last, despite its clinical relevance, our risk score provides no advances in the understanding of the pathogenesis of PAT, e.g., whether PAT is a cause or a consequence of ACS and whether it implies an in situ rather than an embolic process.
Conclusion
We herein propose a simple clinical risk score for the selection of SCD patients at high risk for PAT during an episode of ACS. This score may help select patients for assessment by MDCT during ACS, but needs further prospective validation.
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